Background: Insomnia is a major health issue, and zolpidem is an effective treatment for insomnia. However, high doses of zolpidem can cause dependence, abuse, and withdrawal symptoms, questioning its advantages.
Case Presentation: A 39-year-old woman who has been divorced and unemployed for 2 years was referred to an addiction treatment center with a chief complaint of "seizure-like withdrawal symptoms after consuming high doses of zolpidem (up to 6,000 mg per day) for a decade." These symptoms were in the form of body tremors, nystagmus, stress, anxiety, hot flashes, and sweaty palms. She has been undergoing detoxification by clonazepam for almost 2 months. Except for the first few days, she did not have any withdrawal symptoms, and her insomnia caused by zolpidem has improved.
Conclusion: Chronic abuse of zolpidem can cause dependence, withdrawal symptoms, and abuse. High doses can lead to extreme cravings and dependence. Physicians must manage the withdrawal process.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565798 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2023.1252397 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Homelessness is a growing concern in the United States, especially among people who use drugs (PWUD). The degree of material hardship among this population may be linked to worse health outcomes. PWUD experiencing homelessness in urban areas are increasingly subjected to policies and social treatment, such as forced displacement, which may worsen material hardship.
View Article and Find Full Text PDFTobacco use is the leading cause of death globally and in the U.S. After decades of decline, driven by decreases in combusted tobacco use, nicotine product use has increased due to Electronic Nicotine Delivery Systems (ENDS), also known as e-cigarettes or vapes.
View Article and Find Full Text PDFEffectiveness of interventions to prevent or treat prolonged grief symptoms among families of patients who die in Intensive Care Units: a systematic review protocol.
JBI Evid Synth
January 2025
CINTESIS@RISE, Nursing School of Porto (ESEP), Porto, Portugal.
Objective: The objective of this review is to evaluate the effectiveness of interventions to prevent or treat prolonged grief symptoms among families of patients who die in intensive care units (ICU).
Introduction: Up to 52% of families of patients who die in ICU may be at risk of experiencing prolonged grief symptoms.
Inclusion Criteria: Studies of adult family members (≥18 years) of adult ICU patients (≥18 years) who underwent a treatment withdrawal or withholding decision, and who were exposed to tailored interventions to prevent or treat prolonged grief symptoms before, during, and/or after the patient's death will be considered for inclusion.
Treatment of Inpatient Opioid Withdrawal with Short-Acting Full Agonist Opioids at a Safety-Net Hospital.
J Gen Intern Med
January 2025
University of California, San Francisco, 1001 Potrero Avenue, Bldg 5 Rm 5H06, San Francisco, CA, 94110, USA.
Background: Fentanyl use leads to increased opioid tolerance in people with opioid use disorder, complicating management of opioid withdrawal syndrome. While accepted as gold standard, methadone and buprenorphine may be insufficient to treat acute opioid withdrawal. Short-acting full agonist opioids (SAFAO) may improve treatment in the acute care setting.
View Article and Find Full Text PDFComputational modeling design of novel NMDAR agonist for the treatment of Schizophrenia.
Neurogenetics
January 2025
Department of Biochemistry, College of Medicine, University of Lagos, Lagos State, Nigeria.
Schizophrenia (SZ) is a complex, chronic mental disorder characterized by positive symptoms (such as delusions and hallucinations), negative symptoms (including anhedonia, alogia, avolition, and social withdrawal), and cognitive deficits (affecting attention, processing speed, verbal and visuospatial learning, problem-solving, working memory, and mental flexibility). Extensive animal and clinical studies have emphasized the NMDAR hypofunction hypothesis of SZ. Glycine plays a crucial role as an agonist of NMDAR, enhancing the receptor's affinity for glutamate and supporting normal synaptic function and plasticity, that is, signal transmission between neurons.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!